Malignant urachal neoplasia is one of the rarest cancers encountered in clinical practice, accounting for well under 1% of bladder-associated malignancies. Its rarity translates into fragmented guidance, delayed diagnosis and uncertainty about optimal treatment sequences. Our case report and literature review aimed to consolidate the scattered evidence and clarify what clinicians can meaningfully rely on.
The case followed a 39-year-old man with advanced metastatic disease at presentation, including osseous and pulmonary lesions. After partial cystectomy and multi-agent chemotherapy, early biochemical and radiological improvements highlighted the temporary responsiveness often seen with 5-FU–based regimens. Yet, like many urachal adenocarcinomas, disease progression occurred despite therapy—a reflection of the aggressive biology and the absence of consensus first-line treatment.
By analysing historical chemotherapy protocols, staging systems such as the Sheldon and Mayo scales, and patterns of metastatic spread, our review demonstrated a critical need for consistent data reporting and prospective multicentre collaboration. While individual case responses can be impressive, survival for metastatic disease remains poor, and standardisation of diagnostic and therapeutic approaches is now overdue.
You can read more about this research here.
If you want to understand how this informs what we do at Medly and why we do it, check out Medly, my publications & my current research.
Written by Dr William Maish
MD MBA MPH FHEA JD (in prog.)
Found of Medly & Medly Health
ORCID profile
Google Scholar profile
LinkedIn profile